Clinical Trial Update: An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder [Phase 3]

View source ↗

Summary

An open-label Phase 3 extension trial evaluating the safety and tolerability of licarbazepine at 750–2000 mg/day for manic episodes in Bipolar I Disorder, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Licarbazepine (licarbazepine)

Snippet

Sponsor: Novartis | Conditions: Bipolar I Disorder | Phase 3 | Status: COMPLETED